Cargando…
Study partners: essential collaborators in discovering treatments for Alzheimer’s disease
BACKGROUND: Global leaders have set an ambitious goal of developing interventions to effectively treat or prevent Alzheimer’s disease by 2025. CASE PRESENTATION: Achieving this goal will require clinical trials to test promising interventions, yet Alzheimer’s researchers are confronting a clinical t...
Autores principales: | Largent, Emily A., Karlawish, Jason, Grill, Joshua D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161465/ https://www.ncbi.nlm.nih.gov/pubmed/30261910 http://dx.doi.org/10.1186/s13195-018-0425-4 |
Ejemplares similares
-
Study partners should be required in preclinical Alzheimer’s disease trials
por: Grill, Joshua D., et al.
Publicado: (2017) -
Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials
por: Grill, Joshua D, et al.
Publicado: (2010) -
‘That would be dreadful’: The ethical, legal, and social challenges of sharing your Alzheimer’s disease biomarker and genetic testing results with others
por: Largent, Emily A, et al.
Publicado: (2021) -
Effects of Self-Identification as a Caregiver on Expectations of Public Stigma of Alzheimer’s Disease
por: Stites, Shana D., et al.
Publicado: (2021) -
How Biomarker-Based Diagnosis and Treatment Affect Alzheimer’s Stigma: Results of a Randomized Trial
por: Stites, Shana, et al.
Publicado: (2021)